Innovations In Clinical Neuroscience

NOV-DEC 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: https://innovationscns.epubxp.com/i/924986

Contents of this Issue

Navigation

Page 21 of 83

22 ICNS INNOVATIONS IN CLINICAL NEUROSCIENCE November-December 2017 • Volume 14 • Number 11–12 O R I G I N A L R E S E A R C H ACKNOWLEDGMENTS The authors would like to acknowledge the following authors of the previous study that served as the database for these analyses: Martin T. Strassnig, Tenko Raykov, Cedric O'Gorman, Christopher R. Bowie, Samir Sabbag, Dante Durand, Thomas L. Patterson, Amy Pinkham, and David L. Penn. REFERENCES 1. Bowie C., Leung WW, Reichenberg, et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63(5):505–511. 2. Strauss GP, Sandt AR, Catalano LT, Allen DN. Negative symptoms and depression predict psychological well-being in individuals with schizophrenia. Compr Psychiatry. 2012;53(8):1137–1144. 3. Kirkpatrick B, Fenton WS, Carpenter WT, Jr., Marder S R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214–219. 4. Quinlan T, Roesch S, Granholm E. The role of dysfunctional attitudes in models of negative symptoms and functioning in schizophrenia. Schizophr Res. 2014;157(1-3):182–189. 5. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):149–165. 6. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;39(7):784–788. 7. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. 8. Horan WP, Kring AM, Gur RE, Reise SP, Blanchard JJ. Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res. 2011;132(2- 3):140–145. 9. Kirkpatrick B, Strauss GP, Nguyen L, et al. The Brief Negative Symptom Scale: psychometric properties. Schizophr Bull. 2011;37(2):300–305. 10. Blanchard JJ, Cohen A S. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32(2):238–245. 11. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36(2):359–369. 12. Jang JK, Choi HI, Park S. et al. A two-factor model better explains heterogeneity in negative symptoms: evidence from the positive and negative syndrome scale. Front Psychol. 2016;7:707. 13. Kring AM, Gur R E, Blanchard JJ, et al. The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am J Psychiatry. 2013;170(2):165–172. 14. Strauss GP, Hong LE, Keller WR, et al. Factor structure of the Brief Negative Symptom Scale. Schizophr Res. 2012;142(1-3):96–98. 15. Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatric Res. 2013;47(6):783–789. 16. Strassnig, MT, Raykov T, O'Gorman C, et al. Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity. Schizophr Res. 2015;165(1):76–82. 17. Kalin M, Kaplan S, Gould F, et al. Social cognition, social competence, negative symptoms and social outcomes: inter-relationships in people with schizophrenia. J Psychiatric Res. 2015;68:254– 260. 18. Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr Bull. 2006;32(2):246– 249. 19. Khan A, Liharska L, Harvey PD, et al. Positive and Negative Syndrome Scale (PANSS) negative symptom dimensions across geographical regions: implications for social, Llnguistic, and cultural consistency. Innov Clin Neurosci. 2017;14(11–12)xx–xx 20. First MB, Spitzer RL, Gibbon M, Williams JBW. Structural Clinical Interview for DSM-IV Axis I Disorders (SCID-IV). New York, NY: New York Psychiatric Institute, Biometrics Research; 1997. 21. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999;59 Suppl 20:22–33;quiz 34–57. 22. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing psychopathology and diagnosis. Arch Gen Psychiatry. 1992;49(8):615–623. 23. Harvey PD, Raykov T, Twamley EW, et al. Validating the measurement of real-world functional outcome: Phase I results of the VALERO study. Am J Psychiatry. 2011;168(11):1195–2001. 24. Durand D, Strassnig M, Sabbag S, et al. Factors influencing self-assessment of cognition and functioning in schizophrenia: implications For treatment studies. Eur Neuropsychopharmacol. 2015;25(2):185–191. 25. Pinkham A, Penn DL, Green MF, et al. The Social Cognition Psychometric Evaluation study: results of the expert survey and RAND panel. Schizophr Bull. 2014;40(4):813–823. 26. Schneider LC, Struening EL. SLOF: a behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr. 1983;19(3):9–21. 27. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203–213. 28. Keefe RSE, Blder RM, Harvey, PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31(9):2033–2046. 29. Mausbach BT, Harvey PD, Goldman SR, et al. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007;33(6):1364–1372. 30. Ventura J, Subotnik KL, Gitlin MJ, et al. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr Res. 2015;161(2–3):407- 411. ICNS

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - NOV-DEC 2017